Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRENW | US
-0.00
-5.93%
Healthcare
Diagnostics & Research
31/03/2024
10/10/2024
0.01
0.01
0.01
0.01
Prenetics Global Limited an investment holding company operates as a diagnostics and genetic testing company. Its products include CircleDNA a consumer genetic testing product; and Circle HealthPod a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot an off-the-shelf at-home blood test; Circle Medical a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay Hong Kong.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
332.1%1 month
306.6%3 months
254.4%6 months
317.5%-
-
-
0.01
0.01
-
-
-
-41.58M
-
-
-
-142.81
-
-63.80
-23.71
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.01
Range1M
0.01
Range3M
0.01
Rel. volume
0.16
Price X volume
452.60
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
STRRP | STRRP | Diagnostics & Research | 9.59 | 0 | 0.00% | n/a | 26.85% |
bioAffinity Technologies Inc. Warrant | BIAFW | Diagnostics & Research | 1.1 | 0 | -7.17% | n/a | 40.20% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 12.33 | - |
Ent. to Revenue | - | 39.67 | - |
PE Ratio | - | 39.96 | - |
Price to Book | - | 76.13 | - |
Dividend Yield | - | 1.19 | - |
Std. Deviation (3M) | 254.39 | 62.86 | Riskier |
Debt to Equity | 0.01 | -14.36 | Expensive |
Debt to Assets | 0.01 | 0.34 | Cheaper |
Market Cap | - | 13.17B | - |